alexa Use of Tolvaptan beyond Thirty Days in a Case of Refractory SIADH | Open Access Journals
ISSN: 2161-0959
Journal of Nephrology & Therapeutics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Use of Tolvaptan beyond Thirty Days in a Case of Refractory SIADH

Mamatha Siricilla1, Islam Abudayyeh2 and Ala Abudayyeh1*

1Department of General Internal Medicine & Section of Nephrology at the University Of Texas MD Anderson Cancer Center, Texas, USA

2Department of Cardiology at Loma Linda University, Texas, USA

*Corresponding Author:
Ala Abudayyeh M.D
Assistant Professor, MD Anderson Cancer Center
University of Texas, Division of Internal Medicine
Section of Nephrology, Unit 1468
1400 Pressler Street, Houston
Texas 77030-3722, USA
Tel: (713)745-9331
Fax: (713)563-4491
E-mail: [email protected]

Received Date: August 08, 2015; Accepted Date: December 10, 2015; Published Date: December 17, 2015

Citation: Siricilla M, Abudayyeh I, Abudayyeh A (2015) Use of Tolvaptan beyond Thirty Days in a Case of Refractory SIADH. J Nephrol Ther 6:229. doi:10.4172/2161-0959.1000229

Copyright: © 2015 Siricilla M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nephrology & Therapeutics

Keywords

SIADH; Tolvaptan; Malignancy; Hyponatremia

A 72-year-old man recently diagnosed with amyloidosis involving the mediastinum was evaluated for recurrent symptomatic hyponatremia (as low as sodium level; 106 mEq/L) necessitating hospitalization. The patient was normotensive at presentation. His thyroid function and serum cortisol levels were normal. Laboratory findings were consistent with syndrome of inappropriate antidiuretic hormone (SIADH) with low serum osmolality 260 mOsm/kg, hyponatremia, urine osmolality 366 mOSm/kg and urine sodium of 94 mEq/L. On physical examination no edema was noted.

Patient was initially managed with fluid restriction, salt tablets and diuretics with no improvement in serum sodium levels. Stem cell transplant was planned for treatment of amyloidosis but was delayed because of his severe symptomatic hyponatremia. As a last resort, Tolvaptan (7.5 mg) was started, and his serum sodium level improved to 138 mEq/L (Figure 1), thus facilitating stem cell transplant. Tolvaptan was administered for approximately 60 days to achieve stable serum sodium levels and stopped thereafter.

nephrology-therapeutics-serum

Figure 1: Sodium serum level improved to 138 mEq/L.

Hyponatremia is a common electrolyte abnormality in cancer patients, and it carries a significantly negative prognosis [1]. A study by Doshi et al. [2] showed that hyponatremia is associated with longer hospital stays and higher mortality, contributing to a financial burden of $2289 per day per admission.

Major limitations of currently available therapeutic options (eg, hypertonic saline, fluid restriction, democlocycline) are slow, unpredictable correction and renal dysfunction. Management of hyponatremia can be more challenging in the cancer setting because of the concurrent use of chemotherapeutic agents with associated hydration protocols, and coexistent renal insufficiency. Thus, there is clearly an emerging need for new oral medications with efficacy in treating hyponatremia.

Tolvaptan has been approved in the United States since 2009 for the treatment of clinically significant euvolemia and hypervolemic hyponatremia. Tolvaptan is well tolerated, and no dose adjustment is needed for renal impairment.

In a recent ADPKD (Autosomal polycystic kidney disease) trial [3], Tolvaptan delayed the progression of autosomal polycystic kidney disease using doses greater than 45 mg/day. Three cases of severe liver injury were reported, indicating its potential for further progression to liver failure. Hence, after the aforementioned trial, the U.S. Food and Drug administration (FDA) revised the label for Tolvaptan to specify that its use not extend beyond 30 days.

Although the clinical trials for which it was primarily approved (eg, SIADH, heart failure) were of short duration [3] (i.e., less than 30 days), it was not associated with liver toxicity when administered at much lower doses.

This letter is intended to share our experience using Tolvaptan under special circumstances for a longer duration than approved by the FDA with no undue side effects and overall improvement of outcomes. We hope to encourage the use of this novel drug in a case-dependent manner.

Conflict of interest

The authors have declared that no Conflict of interest exists

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 15th International Conference on Nephrology & Therapeutics
    August 28-30, 2017 Philadelphia, USA
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • World Nephrology Congress
    Osaka, Japan Oct 09-11, 2017
  • 13th World Nephrology Conference
    October 18-19, 2017 Dubai,UAE
  • 16th International Conference on Nephrology
    NOVEMBER 02-03, 2017 Atlanta, USA

Article Usage

  • Total views: 7900
  • [From(publication date):
    February-2016 - Aug 23, 2017]
  • Breakdown by view type
  • HTML page views : 7844
  • PDF downloads :56
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords